STAT+: Bluebird Bio intends to split into two companies, but for now, its troubles are also divided
Splitting Bluebird Bio into two publicly traded companies — one focused on cell therapies for cancer, the other on gene therapy for inherited diseases — is the best fix for the biotech’s recent struggles, CEO Nick Leschly told investors on Monday.
“Two birds are better than one,” said Leschly, speaking on a conference call in which he explained that dividing Bluebird into two companies “creates flexibility for each business,” “sharpens their focus,” and allows for “operational simplicity.”
